CH679372A5 - - Google Patents
Download PDFInfo
- Publication number
- CH679372A5 CH679372A5 CH131289A CH131289A CH679372A5 CH 679372 A5 CH679372 A5 CH 679372A5 CH 131289 A CH131289 A CH 131289A CH 131289 A CH131289 A CH 131289A CH 679372 A5 CH679372 A5 CH 679372A5
- Authority
- CH
- Switzerland
- Prior art keywords
- stage
- benzopyrone
- portions
- preparation
- salt
- Prior art date
Links
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 claims abstract description 42
- 229960000956 coumarin Drugs 0.000 claims abstract description 33
- 238000002360 preparation method Methods 0.000 claims abstract description 19
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- 235000001671 coumarin Nutrition 0.000 claims abstract description 9
- QGNBTYAQAPLTMX-UHFFFAOYSA-L calcium dobesilate Chemical compound [Ca+2].OC1=CC=C(O)C(S([O-])(=O)=O)=C1.OC1=CC=C(O)C(S([O-])(=O)=O)=C1 QGNBTYAQAPLTMX-UHFFFAOYSA-L 0.000 claims abstract description 7
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229960005489 paracetamol Drugs 0.000 claims abstract description 4
- 229960002895 phenylbutazone Drugs 0.000 claims abstract description 4
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000004480 active ingredient Substances 0.000 claims description 11
- 239000011575 calcium Substances 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 9
- IKQCSJBQLWJEPU-UHFFFAOYSA-N 2,5-dihydroxybenzenesulfonic acid Chemical compound OC1=CC=C(O)C(S(O)(=O)=O)=C1 IKQCSJBQLWJEPU-UHFFFAOYSA-N 0.000 claims description 8
- 206010010121 compartment syndrome Diseases 0.000 claims description 7
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 6
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 6
- 208000012659 Joint disease Diseases 0.000 claims description 4
- 230000007310 pathophysiology Effects 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 230000000144 pharmacologic effect Effects 0.000 claims description 3
- 230000000069 prophylactic effect Effects 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 230000001364 causal effect Effects 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 239000000730 antalgic agent Substances 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 abstract description 13
- 230000006872 improvement Effects 0.000 abstract description 6
- 210000000988 bone and bone Anatomy 0.000 abstract description 5
- 230000001926 lymphatic effect Effects 0.000 abstract description 3
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical class CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 abstract 1
- 230000002917 arthritic effect Effects 0.000 abstract 1
- 230000002045 lasting effect Effects 0.000 abstract 1
- 230000037396 body weight Effects 0.000 description 10
- 241000700159 Rattus Species 0.000 description 7
- 230000000202 analgesic effect Effects 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 230000000711 cancerogenic effect Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 210000002751 lymph Anatomy 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 231100000357 carcinogen Toxicity 0.000 description 3
- 239000003183 carcinogenic agent Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 210000001365 lymphatic vessel Anatomy 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000035943 smell Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000008728 vascular permeability Effects 0.000 description 2
- 208000010444 Acidosis Diseases 0.000 description 1
- 238000010953 Ames test Methods 0.000 description 1
- 231100000039 Ames test Toxicity 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 241001504519 Papio ursinus Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 206010043275 Teratogenicity Diseases 0.000 description 1
- VWNJNGUJNHKZMC-UHFFFAOYSA-N [Ca].C1(O)=C(O)C(=CC=C1)S(=O)(=O)O Chemical compound [Ca].C1(O)=C(O)C(=CC=C1)S(=O)(=O)O VWNJNGUJNHKZMC-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- -1 benzopyronyl Chemical group 0.000 description 1
- 201000007180 bile duct carcinoma Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000001700 effect on tissue Effects 0.000 description 1
- 210000002310 elbow joint Anatomy 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 210000000003 hoof Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000000281 joint capsule Anatomy 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000243 mutagenic effect Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940124641 pain reliever Drugs 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000003128 rodenticide Substances 0.000 description 1
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000001137 tarsal bone Anatomy 0.000 description 1
- 231100000211 teratogenicity Toxicity 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229960003232 troxerutin Drugs 0.000 description 1
- 230000009724 venous congestion Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH131289A CH679372A5 (da) | 1989-04-07 | 1989-04-07 | |
| PCT/CH1990/000072 WO1990011759A1 (de) | 1989-04-07 | 1990-03-15 | 2-stufen-zubereitung mit cumarin oder dobesilat-calcium zur behandlung von osteoarthrose |
| EP19900903746 EP0419604A1 (de) | 1989-04-07 | 1990-03-15 | 2-stufen-zubereitung mit cumarin oder dobesilat-calcium zur behandlung von osteoarthrose |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH131289A CH679372A5 (da) | 1989-04-07 | 1989-04-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH679372A5 true CH679372A5 (da) | 1992-02-14 |
Family
ID=4207501
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH131289A CH679372A5 (da) | 1989-04-07 | 1989-04-07 |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP0419604A1 (da) |
| CH (1) | CH679372A5 (da) |
| WO (1) | WO1990011759A1 (da) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5645081A (en) * | 1991-11-14 | 1997-07-08 | Wake Forest University | Method of treating tissue damage and apparatus for same |
| RU2250769C2 (ru) * | 2003-06-05 | 2005-04-27 | Главный клинический госпиталь Министерства внутренних дел Российской Федерации (ГКГ МВД РФ) | Способ лечения остеоартроза |
| WO2008020033A1 (en) * | 2006-08-16 | 2008-02-21 | Action Medicines, S.L. | Use of 2,5-dihydroxybenzene derivatives for the treatment of arthritis and pain |
| DE502007002101D1 (de) * | 2007-03-12 | 2010-01-07 | Dobavet Gmbh | Arzneimittel mit Dobesilat-Calcium zur Behandlung und Prophylaxe von Sehnenerkrankungen |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU581885B2 (en) * | 1984-03-01 | 1989-03-09 | Lamorna Investments Proprietary Limited | Treatment of high protein oedemas by direct application of benzo-pyrones |
| US5096887A (en) * | 1984-03-01 | 1992-03-17 | Lamorna Investments Proprietary Limited | Treatment of high protein oedemas |
-
1989
- 1989-04-07 CH CH131289A patent/CH679372A5/de not_active IP Right Cessation
-
1990
- 1990-03-15 EP EP19900903746 patent/EP0419604A1/de not_active Withdrawn
- 1990-03-15 WO PCT/CH1990/000072 patent/WO1990011759A1/de not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO1990011759A1 (de) | 1990-10-18 |
| EP0419604A1 (de) | 1991-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69822665T2 (de) | Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14-dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen | |
| DE69003229T2 (de) | Entzündungshemmendes Mittel in einer Zusammensetzung. | |
| DE69519937T2 (de) | Polyamin-verbindungen zur behandlung von proliferativer erkrankungen | |
| DE69028712T2 (de) | Zusammensetzung zur behandlung entzündlicher darmerkrankungen | |
| AT393221B (de) | Mittel mit zerstoerender wirkung auf maligne tumore, verfahren zu dessen herstellung und praeparation zur anwendung in der therapie von krebskranken | |
| DE3907649C2 (de) | Arzneimittel, geeignet bei der Bekämpfung von Viren und zur Immunstimulierung | |
| CH660969A5 (de) | Verwendung von thiadiazinverbindungen. | |
| DE69024053T2 (de) | Behandlung zur ermässigung von ödem und muskelschäden. | |
| DE69413090T2 (de) | Verwendung von 5-Amino-Phthaloylhydrazid als antihypoxisches und defensives Mittel | |
| DE2921312A1 (de) | Pharmazeutisches mittel und dessen verwendung bei einer vollstaendig parenteralen ernaehrung | |
| DE2803869A1 (de) | Injizierbare embolisations- und okklusionsloesung | |
| DE69103908T2 (de) | Verbessertes behandlungsverfahren für krebs. | |
| CH679372A5 (da) | ||
| EP1397128B1 (de) | Kappa-opiatagonist für die behandlung der reizblase | |
| DE60124516T2 (de) | Kombination des lezithins mit ascorbinsäure | |
| DE3152319T1 (da) | ||
| DE60216292T2 (de) | Calciumtrifluoracetat mit zytotoxischer wirkung | |
| DE1900772C3 (de) | Salz aus N,N-Dimethylbiguanid und p-Chlorphenoxyessigsäure sowie dieses enthaltende Arzneimittel | |
| Best et al. | Studies in experimental shock | |
| EP0670721B1 (de) | Arzneimittel zur behandlung und prophylaxe von knochen- und gelenkserkrankungen | |
| Kallfelz et al. | Correlation between 47Ca absorption and intestinal calcium-binding activity in the golden hamster | |
| DE1964504A1 (de) | Arzneimittelzubereitung mit einem Gehalt an 3-Butylamino-4-phenoxy-5-sulfamyl-benzoesaeure und deren Salzen | |
| DE69721077T2 (de) | Verwendung von 2-methoxyphenyl-1-methyl-5p-methyl-benzoylpyrrol-2-acetamido-acetat zur herstellung eines antientzündungsmittels mit vorbeugung von magenhypersekretion und nierenfunktionsstörung | |
| DE2844534C2 (da) | ||
| Mann | The liver and medical progress |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased |